Prognostic and Predictive Analyses of Circulating Plasma Biomarkers in Men with Metastatic Castration Resistant Prostate Cancer Treated with Docetaxel/Prednisone with or without Bevacizumab

0
18
CALGB 90401 (Alliance) was a Phase III trial of 1050 patients with metastatic castration-resistant prostate cancer comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone.
[Prostate Cancer And Prostatic Diseases]
Abstract